Phosphatidylcholine-specific phospholipase C inhibition reduces HER2-overexpression, cell proliferation and in vivo tumor growth in a highly tumorigenic ovarian cancer model

Antagonizing the oncogenic effects of human epidermal growth factor receptor 2 (HER2) with current anti-HER2 agents has not yet yielded major progress in the treatment of advanced HER2-positive epithelial ovarian cancer (EOC). Using preclinical models to explore alternative molecular mechanisms affe...

Descripción completa

Detalles Bibliográficos
Autores principales: Paris, Luisa, Podo, Franca, Spadaro, Francesca, Abalsamo, Laura, Pisanu, Maria Elena, Ricci, Alessandro, Cecchetti, Serena, Altabella, Luisa, Buoncervello, Maria, Lozneanu, Ludmila, Bagnoli, Marina, Ramoni, Carlo, Canevari, Silvana, Mezzanzanica, Delia, Iorio, Egidio, Canese, Rossella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589638/
https://www.ncbi.nlm.nih.gov/pubmed/28903399
http://dx.doi.org/10.18632/oncotarget.18992

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589638/
https://www.ncbi.nlm.nih.gov/pubmed/28903399
http://dx.doi.org/10.18632/oncotarget.18992

Ejemplares similares